Primary Biliary Cirrhosis. Therapeutic Advances.

Clinics in Liver Disease

Volumn 17, Issue 2, 2013, Pages 229-242

  Czul, Frank ^a   Peyton, Adam ^a   Levy, Cynthia ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

6 Ethyl chenodeoxycholic acid; Fibrates; Primary biliary cirrhosis; Therapeutics; Ursodeoxycholic acid

Indexed keywords

ANTIRETROVIRUS AGENT; AZATHIOPRINE; BEZAFIBRATE; BILE ACID; BUDESONIDE; COLCHICINE; COLECALCIFEROL; FARNESOID X RECEPTOR; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GLUCOCORTICOID RECEPTOR; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; LAMIVUDINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OBETICHOLIC ACID; PREDNISOLONE; PREGNANE X RECEPTOR; RITUXIMAB; TETRATHIOMOLYBDIC ACID; THIOPURINE METHYLTRANSFERASE; URSODEOXYCHOLIC ACID; ZIDOVUDINE;

ADD ON THERAPY; ADJUVANT THERAPY; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ASTHMA; BILE ACID METABOLISM; BILE ACID SYNTHESIS; BILE FLOW; BINDING AFFINITY; BONE MARROW DEPRESSION; BONE MARROW SUPPRESSION; CELL CYCLE ARREST; CELL MIGRATION; DIABETES MELLITUS; DOSE RESPONSE; DOWN REGULATION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG UPTAKE; END STAGE LIVER DISEASE; GRANULOCYTE; HEPATITIS; HISTOPATHOLOGY; HUMAN; IMMUNOMODULATION; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; LONG TERM CARE; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NONHUMAN; OSTEOPOROSIS; PHAGOCYTOSIS; PORTAL VEIN THROMBOSIS; PRIMARY BILIARY CIRRHOSIS; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SMALL INTESTINE ABSORPTION; SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UPREGULATION; VITAMIN SUPPLEMENTATION;

CHOLAGOGUES AND CHOLERETICS; HUMANS; LIVER CIRRHOSIS, BILIARY; LIVER TRANSPLANTATION; URSODEOXYCHOLIC ACID;

EID: 84875625949     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2012.12.003     Document Type: Review

References (75)

1. Crosignani A., Battezzati P.M., Invernizzi P., et al. Clinical features and management of primary biliary cirrhosis. World J Gastroenterol 2008, 14(21):3313-3327.
2. Selmi C., Mayo M.J., Bach N., et al. Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology 2004, 127(2):485-492.
3. Lazaridis K.N., Talwalkar J.A. Clinical epidemiology of primary biliary cirrhosis: incidence, prevalence, and impact of therapy. J Clin Gastroenterol 2007, 41(5):494-500.
4. Kim W.R., Lindor K.D., Locke G.R., et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 2000, 119(6):1631-1636.
5. Inoue K., Hirohara J., Nakano T., et al. Prediction of prognosis of primary biliary cirrhosis in Japan. Liver 1995, 15(2):70-77.
6. Prince M., Chetwynd A., Newman W., et al. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 2002, 123(4):1044-1051.
7. Talwalkar J.A., Souto E., Jorgensen R.A., et al. Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2003, 1(4):297-302.
8. Corpechot C., Carrat F., Bahr A., et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005, 128(2):297-303.
9. Mattalia A., Quaranta S., Leung P.S., et al. Characterization of antimitochondrial antibodies in health adults. Hepatology 1998, 27(3):656-661.
10. Lindor K.D., Gershwin M.E., Poupon R., et al. Primary biliary cirrhosis. Hepatology 2009, 50(1):291-308.
11. Berg P.A., Klein R. Heterogeneity of antimitochondrial antibodies. Semin Liver Dis 1989, 9(2):103-116.
12. Berg P.A., Klein R. Mitochondrial antigen/antibody systems in primary biliary cirrhosis: revisited. Liver 1995, 15(6):281-292.
13. Invernizzi P., Podda M., Battezzati P.M., et al. Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J Hepatol 2001, 34(3):366-372.
14. Muratori L., Granito A., Muratori P., et al. Antimitochondrial antibodies and other antibodies in primary biliary cirrhosis: diagnostic and prognostic value. Clin Liver Dis 2008, 12(2):261-276. vii.
15. Nakamura M., Kondo H., Mori T., et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007, 45(1):118-127.
16. Invernizzi P., Crosignani A., Battezzati P.M., et al. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology 1997, 25(5):1090-1095.
17. Kim W.R., Poterucha J.J., Jorgensen R.A., et al. Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation. Hepatology 1997, 26(1):22-26.
18. Scheuer P.J. Primary biliary cirrhosis: diagnosis, pathology and pathogenesis. Postgrad Med J 1983, 59(Suppl 4):106-115.
19. Heathcote E.J. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 2000, 31(4):1005-1013.
20. Lindor K. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. N Engl J Med 2007, 357(15):1524-1529.
21. Poupon R. Primary biliary cirrhosis: a 2010 update. J Hepatol 2010, 52(5):745-758.
22. Paumgartner G., Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002, 36(3):525-531.
23. Lazaridis K.N., Gores G.J., Lindor K.D. Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders. J Hepatol 2001, 35(1):134-146.
24. Roma M.G., Toledo F.D., Boaglio A.C., et al. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications. Clin Sci (Lond) 2011, 121(12):523-544.
25. Rodrigues C.M., Ma X., Linehan-Stieers C., et al. Ursodeoxycholic acid prevents cytochrome c release in apoptosis by inhibiting mitochondrial membrane depolarization and channel formation. Cell Death Differ 1999, 6(9):842-854.
26. Bergamini A., Dini L., Baiocchi L., et al. Bile acids with differing hydrophilic-hydrophobic properties do not influence cytokine production by human monocytes and murine Kupffer cells. Hepatology 1997, 25(4):927-933.
27. Balasubramaniam K., Grambsch P.M., Wiesner R.H., et al. Diminished survival in asymptomatic primary biliary cirrhosis. A prospective study. Gastroenterology 1990, 98(6):1567-1571.
28. Corpechot C., Abenavoli L., Rabahi N., et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008, 48(3):871-877.
29. Gong Y., Huang Z.B., Christensen E., et al. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2008, (3). CD000551.
30. Poupon R.E., Lindor K.D., Cauch-Dudek K., et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997, 113(3):884-890.
31. Lindor K.D., Jorgensen R.A., Therneau T.M., et al. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc 1997, 72(12):1137-1140.
32. Lee J., Belanger A., Doucette J.T., et al. Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2007, 5(11):1313-1315.
33. Liermann Garcia R.F., Evangelista Garcia C., McMaster P., et al. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology 2001, 33(1):22-27.
34. Kuiper E.M., Hansen B.E., Metselaar H.J., et al. Trends in liver transplantation for primary biliary cirrhosis in the Netherlands 1988-2008. BMC Gastroenterol 2010, 10:144.
35. Jorgensen R.A., Dickson E.R., Hofmann A.F., et al. Characterisation of patients with a complete biochemical response to ursodeoxycholic acid. Gut 1995, 36(6):935-938.
36. Corpechot C., Chazouilleres O., Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol 2011, 55(6):1361-1367.
37. Pares A., Caballeria L., Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006, 130(3):715-720.
38. Kumagi T., Guindi M., Fischer S.E., et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol 2010, 105(10):2186-2194.
39. Kuiper E.M., Hansen B.E., de Vries R.A., et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009, 136(4):1281-1287.
40. Azemoto N., Kumagi T., Abe M., et al. Biochemical response to ursodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis. Hepatol Res 2011, 41(4):310-317.
41. Kaplan M.M., Poupon R. Treatment with immunosuppressives in patients with primary biliary cirrhosis who fail to respond to ursodiol. Hepatology 2009, 50(2):652.
42. Angulo P., Jorgensen R.A., Lindor K.D. Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: is a double dosage worthwhile?. Am J Gastroenterol 2001, 96(11):3152-3157.
43. Combes B., Emerson S.S., Flye N.L., et al. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology 2005, 42(5):1184-1193.
44. Giljaca V., Poropat G., Stimac D., et al. Methotrexate for primary biliary cirrhosis. Cochrane Database Syst Rev 2010, (5). CD004385.
45. Gong Y., Gluud C. Colchicine for primary biliary cirrhosis. Cochrane Database Syst Rev 2004, (2). CD004481.
46. Leung J., Bonis P.A., Kaplan M.M. Colchicine or methotrexate, with ursodiol, are effective after 20 years in a subset of patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol 2011, 9(9):776-780.
47. Gong Y., Christensen E., Gluud C. Azathioprine for primary biliary cirrhosis. Cochrane Database Syst Rev 2007, (3). CD006000.
48. Greenberg G.R., Feagan B.G., Martin F., et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994, 331(13):836-841.
49. Rautiainen H., Karkkainen P., Karvonen A.L., et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology 2005, 41(4):747-752.
50. Leuschner M., Maier K.P., Schlichting J., et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology 1999, 117(4):918-925.
51. Hempfling W., Grunhage F., Dilger K., et al. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology 2003, 38(1):196-202.
52. Sievers T.M., Rossi S.J., Ghobrial R.M., et al. Mycophenolate mofetil. Pharmacotherapy 1997, 17(6):1178-1197.
53. Talwalkar J.A., Angulo P., Keach J.C., et al. Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. J Clin Gastroenterol 2005, 39(2):168-171.
54. Askari F., Innis D., Dick R.B., et al. Treatment of primary biliary cirrhosis with tetrathiomolybdate: results of a double-blind trial. Transl Res 2010, 155(3):123-130.
55. Devlin J., O'Grady J. Indications for referral and assessment in adult liver transplantation: a clinical guideline. British Society of Gastroenterology. Gut 1999, 45(Suppl 6):VI1-VI22.
56. Mendes F., Couto C.A., Levy C. Recurrent and de novo autoimmune liver diseases. Clin Liver Dis 2011, 15(4):859-878.
57. Jacob D.A., Neumann U.P., Bahra M., et al. Long-term follow-up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients. Clin Transplant 2006, 20(2):211-220.
58. Jacob D.A., Bahra M., Schmidt S.C., et al. Mayo risk score for primary biliary cirrhosis: a useful tool for the prediction of course after liver transplantation?. Ann Transplant 2008, 13(3):35-42.
59. MacQuillan G.C., Neuberger J. Liver transplantation for primary biliary cirrhosis. Clin Liver Dis 2003, 7(4):941-956. ix.
60. Neuberger J. Liver transplantation for primary biliary cirrhosis. Autoimmun Rev 2003, 2(1):1-7.
61. Dohmen K., Mizuta T., Nakamuta M., et al. Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol 2004, 10(6):894-898.
62. Iwasaki S., Akisawa N., Saibara T., et al. Fibrate for treatment of primary biliary cirrhosis. Hepatol Res 2007, 37(Suppl 3):S515-S517.
63. Iwasaki S., Ohira H., Nishiguchi S., et al. The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study. Hepatol Res 2008, 38(6):557-564.
64. Walker L.J., Newton J., Jones D.E., et al. Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2009, 49(1):337-338. [author reply: 338].
65. Levy C., Peter J.A., Nelson D.R., et al. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther 2011, 33(2):235-242.
66. Honda A., Ikegami T., Nakamuta M., et al. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology 2012, [Epub ahead of print].
67. Mason A., Luketic V., Lindor K., et al. 2 Farnesoid-X receptor agonists: a new class of drugs for the treatment of PBC? an international study evaluating the addition of INT-747 to ursodeoxycholic acid. J Hepatol 2010, 52:S1-S2.
68. Mason A.L., Farr G.H., Xu L., et al. Pilot studies of single and combination antiretroviral therapy in patients with primary biliary cirrhosis. Am J Gastroenterol 2004, 99(12):2348-2355.
69. Mason A.L., Lindor K.D., Bacon B.R., et al. Clinical trial: randomized controlled trial of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol. Aliment Pharmacol Ther 2008, 28(7):886-894.
70. Myers R., Shaheen A.A., Swain M.G., et al. Rituximab for primary biliary cirrhosis (PBC) refractory to ursodeoxycholic acid (UDCA). Hepatology 2007, 46(S1):532A-631A.
71. Tsuda M., Moritoki Y., Lian Z.X., et al. Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology 2012, 55(2):512-521.
72. Allina J., Hu B., Sullivan D.M., et al. Anti-CD16 autoantibodies and delayed phagocytosis of apoptotic cells in primary biliary cirrhosis. J Autoimmun 2008, 30(4):238-245.
73. Allina J., Stanca C.M., Garber J., et al. T cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosis. J Autoimmun 2006, 27(4):232-241.
74. Allina J., Stanca C.M., Delisser M., et al. High dose vitamin D3 treatment enhances macrophage phagocytosis of apoptotic cells and lowers bilirubin levels in PBC. Hepatology 2008, 48(S1):706A.
75. Corpechot C., Gaouar F., Chazoilleres O., et al. Is biochemical response to ursodeoxycholic acid therapy impacted by vitamin D plasma level in patients with primary biliary cirrhosis?. Hepatology 2012, 56(S1):1137A.